Skip to main content
Premium Trial:

Request an Annual Quote

Eric Fung, Leslie Browne, James Meer, Ken Welsh, Vladimir Vapnik, Paul Duffy


Eric Fung has been promoted by Ciphergen to the position of vice president, clinical and medical affairs, in its new diagnostics division. Fung will manage clinical and medical research underlying the company’s clinical diagnostics business initiative in the area of protein molecular diagnostics.

Fung, who was most recently director of clinical affairs at Ciphergen, joined the company in 2000 as a lead scientist in its Biomarker Discovery Center laboratories, where he managed Ciphergen’s Collaborations with academic and pharmaceutical companies. Before joining Ciphergen, he was a Howard Hughes sponsored researcher at Stanford University, in Richard Scheller’s lab. Fung received his MD and PhD degree in molecular neuroscience from Johns Hopkins University School of Medicine, and has a BS in biology from California Institute of Technology. He is also currently an Adjunct Assistant Professor in the Department of Pathology at Johns Hopkins University School of Medicine.

Leslie Browne has been appointed president and chief executive officer of Pharmacopeia Drug Discovery. Browne has most recently been chief operating officer of Iconix Pharmaceuticals, which does chemogenomics, and chief operating officer of GeneTrace, a functional genomics company. Between 1990 to 2000 he held senior positions at Berlex/ Schering AG, and before that, held positions at Ciba Geigy. Browne received his PhD from the University of Michigan and was an NIH Postdoctoral Fellow at Harvard with Nobel laureate R.B. Woodward.

James Meer has been appointed vice president, chief financial officer, secretary, and treasurer of Pharmos. Prior to joining Pharmos, Meer was a strategic consultant to specialty pharmaceutical and biotech firms. Meer served eight years as vice president and treasurer of Schein Pharmaceutical where he was responsible for capital formation, including a successful IPO, strategic planning and investor relations. He has also held positions at EnviroSource, John Labatt, and General Host Corporation. Meer holds an MBA from Pace University and a BA in Economics from Rutgers College.

Ken Welsh has been appointed to the scientific advisory board of Health Discovery Corporation, a biotechnology company focused on biomarker and pathway discovery for diagnostic markers and drug targets. Welsh is currently a professor of clinical genomics at Royal Brompton Hospital and Imperial College in London. He is also a science advisor to the West London Transplant Center, and a visiting professor at Oxford University and the University of Utrecht. He received his Bsc, PhD, and DSc from Newcastle University.

Health Discovery Corporation also has named Vladimir Vapnik to its scientific advisory board. Vapnik, who won the Humboldt Research award in 2003, is currently a senior researcher at NEC Research. He has worked for AT&T Bell Laboratories and AT&T Labs-Research.

Alamo Pharmaceuticals has appointed Paul Duffy executive vice president. Duffy comes to the Beverly Hills, Calif., pharmaceutical CRO and marketing firm from Novartis, where he managed the marketing and sales of Clozaril (clozapine.) as the head of the neuroscience sales group.


Filed under

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.